12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Precision Therapeutics, Rosetta Genomics sales and marketing update

Rosetta and Precision launched the miRview mets2 assay in the U.S. to identify the primary origin of tumor of uncertain or unknown origin. miRview mets2 is...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >